A promising new member of the tetracycline class of antibiotics: eravacycline. Structurally similar to tigecycline but with multiple times the efficacy against gram-positive cocci and gram-negative bacilli, this antibiotic just finished its first phase III clinical trial for the treatment of urinary tract infections. It’s being investigated as both an oral and intravenous treatment option. Like other tetracyclines, it acts as a protein synthesis inhibitor causing bacteriostatic effects at lower concentrations and bactericidal effects only at high concentrations.

Read more here: http://link.springer.com/article/10.1007%2Fs40265-016-0545-8

Find Eravacycline here at TOKU-E.com: com/Eravacycline-P3951